Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging treatment landscape of non-muscle invasive bladder cancer.
Valenza C, Antonarelli G, Giugliano F, Aurilio G, Verri E, Briganti A, Curigliano G, Necchi A. Valenza C, et al. Among authors: antonarelli g. Expert Opin Biol Ther. 2022 Jun;22(6):717-734. doi: 10.1080/14712598.2022.2082869. Epub 2022 May 31. Expert Opin Biol Ther. 2022. PMID: 35634893 Review.
Harmonizing PD-L1 testing in metastatic triple negative breast cancer.
Giugliano F, Antonarelli G, Tarantino P, Cortes J, Rugo HS, Curigliano G. Giugliano F, et al. Among authors: antonarelli g. Expert Opin Biol Ther. 2022 Mar;22(3):345-348. doi: 10.1080/14712598.2022.2021180. Epub 2021 Dec 29. Expert Opin Biol Ther. 2022. PMID: 34930070 No abstract available.
Targeting brain metastases in breast cancer.
Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Corti C, et al. Among authors: antonarelli g. Cancer Treat Rev. 2022 Feb;103:102324. doi: 10.1016/j.ctrv.2021.102324. Epub 2021 Dec 16. Cancer Treat Rev. 2022. PMID: 34953200 Review.
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Attili I, Valenza C, Santoro C, Antonarelli G, Trillo Aliaga P, Del Signore E, Catania C, Spitaleri G, Passaro A, de Marinis F. Attili I, et al. Among authors: antonarelli g. Front Oncol. 2022 Aug 10;12:980765. doi: 10.3389/fonc.2022.980765. eCollection 2022. Front Oncol. 2022. PMID: 36033444 Free PMC article.
30 results